Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association

PB Duell, FK Welty, M Miller, A Chait… - … , and vascular biology, 2022 - Am Heart Assoc
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

[HTML][HTML] Role of diet and gut microbiota on colorectal cancer immunomodulation

CV De Almeida, MR de Camargo, E Russo… - World journal of …, 2019 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers, and it is
characterized by genetic and epigenetic alterations, as well as by inflammatory cell …

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by …

A Flint, G Andersen, P Hockings… - Alimentary …, 2021 - Wiley Online Library
Background Glucagon‐like peptide‐1 receptor agonists may be a treatment option in
patients with non‐alcoholic fatty liver disease (NAFLD). Aims To investigate the effects of …

[HTML][HTML] Current status, problems, and perspectives of non-alcoholic fatty liver disease research

N Tanaka, T Kimura, N Fujimori, T Nagaya… - World journal of …, 2019 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease that can lead to
liver cirrhosis, liver cancer, and ultimately death. NAFLD is pathologically classified as non …

Triglyceride glucose index and related parameters (triglyceride glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver …

ME Khamseh, M Malek, R Abbasi, H Taheri… - … syndrome and related …, 2021 - liebertpub.com
Background: The triglyceride glucose (TyG) index has been proposed as a reliable
surrogate marker for nonalcoholic fatty liver disease (NAFLD). Furthermore, NAFLD is …

Non-invasive biomarkers of nonalcoholic steatohepatitis: the FNIH NIMBLE project

AJ Sanyal, SS Shankar, RA Calle, AE Samir… - Nature medicine, 2022 - nature.com
ER, DJF, CLV and JFT are supported by the UK Medical Research Council (grant
MC_UU_00004/06). DJF and PJG are supported in part by Prostate Cancer UK (grant RIA …

Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship

CM Muzica, C Sfarti, A Trifan, S Zenovia… - Canadian Journal of …, 2020 - Wiley Online Library
Worldwide, the leading cause of chronic liver disease is represented by nonalcoholic fatty
liver disease (NAFLD) which has now become a global epidemic of the 21st century …

[HTML][HTML] Nonalcoholic fatty liver disease: review of management for primary care providers

R Basu, M Noureddin, JM Clark - Mayo Clinic Proceedings, 2022 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver
disease in the United States and worldwide. The progressive form of NAFLD, nonalcoholic …

[HTML][HTML] Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease

A Campos-Murguía, A Ruiz-Margáin… - World journal of …, 2020 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is among the most frequent etiologies of cirrhosis
worldwide, and it is associated with features of metabolic syndrome; the key factor …

[HTML][HTML] Nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease

G Hassen, A Singh, G Belete, N Jain, I De la Hoz… - Cureus, 2022 - ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty
liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis …